Development of an Indirect ELISA for the Detection of Lactoferrin in Type 2 Diabetes Plasma: A Novel Approach

IF 1.7 4区化学 Q3 CHEMISTRY, ANALYTICAL

Current Analytical Chemistry Pub Date : 2024-02-12 DOI:10.2174/0115734110298646240206061830

Amani Alhalwani

{"title":"Development of an Indirect ELISA for the Detection of Lactoferrin in Type 2 Diabetes Plasma: A Novel Approach","authors":"Amani Alhalwani","doi":"10.2174/0115734110298646240206061830","DOIUrl":null,"url":null,"abstract":"Background: In biological systems, lactoferrin (LF) is a crucial protein for protecting the body against diseases and pathogens that can affect both humans and animals. LF is a multifunction protein that binds to different surface receptors to stimulate the innate immune system. In diabetes, lactoferrin has a direct association with inflammation. The effects of inflammation interaction are unknown but reasonably could include changes in LF, a body protein whose changed concentration correlates with type 2 diabetes (T2D). The LF content in plasma has been used as a disease biomarker, and there is a need for convenient and reliable assays. Method: An innovative indirect enzyme-linked immunosorbent assay (ELISA) was developed and applied to measure circulating lactoferrin levels as an inflammation marker in human samples, including healthy and type 2 diabetes. Results: Under optimized conditions, the proposed indirect ELISA was evaluated and linearly responded to LF standards in a 0.05–0.5 µgmL−1 range. The limit of detection (LOD) was 0.05 µgmL−1, and a reliable limit of quantification (LOQ) was 0.240 µgmL−1 . Conclusion: The developed assay showed both specificity and reproducibility, indicating the utility of this indirect ELISA in LF monitoring. This study provides a definitive indirect ELISA protocol to detect various lactoferrin antigens with accurate, reliable, and reproducible data, and it could be applied for diagnosing lactoferrin-related diseases, such as type 2 diabetes. Our innovative approach provides a relatively cost-effective, sensitive, and precise way to assess LF in various human plasmas.","PeriodicalId":10742,"journal":{"name":"Current Analytical Chemistry","volume":"54 1","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Analytical Chemistry","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.2174/0115734110298646240206061830","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In biological systems, lactoferrin (LF) is a crucial protein for protecting the body against diseases and pathogens that can affect both humans and animals. LF is a multifunction protein that binds to different surface receptors to stimulate the innate immune system. In diabetes, lactoferrin has a direct association with inflammation. The effects of inflammation interaction are unknown but reasonably could include changes in LF, a body protein whose changed concentration correlates with type 2 diabetes (T2D). The LF content in plasma has been used as a disease biomarker, and there is a need for convenient and reliable assays. Method: An innovative indirect enzyme-linked immunosorbent assay (ELISA) was developed and applied to measure circulating lactoferrin levels as an inflammation marker in human samples, including healthy and type 2 diabetes. Results: Under optimized conditions, the proposed indirect ELISA was evaluated and linearly responded to LF standards in a 0.05–0.5 µgmL−1 range. The limit of detection (LOD) was 0.05 µgmL−1, and a reliable limit of quantification (LOQ) was 0.240 µgmL−1 . Conclusion: The developed assay showed both specificity and reproducibility, indicating the utility of this indirect ELISA in LF monitoring. This study provides a definitive indirect ELISA protocol to detect various lactoferrin antigens with accurate, reliable, and reproducible data, and it could be applied for diagnosing lactoferrin-related diseases, such as type 2 diabetes. Our innovative approach provides a relatively cost-effective, sensitive, and precise way to assess LF in various human plasmas.

查看原文本刊更多论文

开发用于检测 2 型糖尿病血浆中乳铁蛋白的间接酶联免疫吸附试验：一种新方法

背景：在生物系统中，乳铁蛋白（LF）是保护机体免受疾病和病原体侵袭的重要蛋白质，可影响人类和动物。乳铁蛋白是一种多功能蛋白质，可与不同的表面受体结合，刺激先天性免疫系统。在糖尿病中，乳铁蛋白与炎症直接相关。炎症相互作用的影响尚不清楚，但合理的可能包括乳铁蛋白的变化，这种体内蛋白质浓度的变化与 2 型糖尿病（T2D）有关。血浆中的乳铁蛋白含量已被用作疾病的生物标志物，因此需要方便可靠的检测方法。方法：开发了一种创新的间接酶联免疫吸附测定法（ELISA），用于测定人体样本（包括健康样本和 2 型糖尿病样本）中作为炎症标志物的循环乳铁蛋白水平。结果显示在优化条件下，对所提出的间接酶联免疫吸附测定进行了评估，该测定与乳铁蛋白标准品在 0.05-0.5 µgmL-1 范围内呈线性反应。检测限（LOD）为 0.05 µgmL-1，可靠的定量限（LOQ）为 0.240 µgmL-1。结论所开发的检测方法具有特异性和可重复性，表明这种间接酶联免疫吸附测定法可用于低浓度监测。这项研究提供了一种检测各种乳铁蛋白抗原的明确的间接酶联免疫吸附试验方案，其数据准确、可靠、可重复，可用于诊断乳铁蛋白相关疾病，如 2 型糖尿病。我们的创新方法为评估各种人体血浆中的乳铁蛋白提供了一种相对经济、灵敏和精确的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Analytical Chemistry 化学-分析化学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

9 months

期刊介绍： Current Analytical Chemistry publishes full-length/mini reviews and original research articles on the most recent advances in analytical chemistry. All aspects of the field are represented, including analytical methodology, techniques, and instrumentation in both fundamental and applied research topics of interest to the broad readership of the journal. Current Analytical Chemistry strives to serve as an authoritative source of information in analytical chemistry and in related applications such as biochemical analysis, pharmaceutical research, quantitative biological imaging, novel sensors, and nanotechnology.